Operaciones Astria Therapeutics, Inc. - ATXS CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | - | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024874% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.002651% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | N/A |
Abrir* | N/A |
Cambio de 1 año* | N/A |
Rango del día* | N/A |
Rango de 52 semanas | 2.36-16.28 |
Volumen medio (10 días) | 303.40K |
Volumen medio (3 meses) | 4.82M |
Capitalización de mercado | 353.75M |
Ratio P/E | -100.00K |
Acciones en circulación | 27.99M |
Ingresos | N/A |
EPS | -3.62 |
Dividendo (Rendimiento %) | N/A |
Beta | 0.91 |
Próxima fecha de resultados | May 10, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|
Astria Therapeutics, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 53.503 | 194.976 | 37.435 | 27.088 | 26.371 |
Gastos de venta/general/administración Gastos, total | 19.239 | 14.807 | 11.845 | 8.771 | 9.329 |
Investigación y desarrollo | 34.264 | 180.169 | 25.59 | 18.317 | 17.042 |
Ingresos de explotación | -53.503 | -194.976 | -37.435 | -27.088 | -26.371 |
Ingresos por intereses (gastos), netos No operativos | 1.724 | 0.122 | 0.236 | 0.845 | 0.325 |
Otros, netos | -0.055 | -0.058 | -0.101 | -0.05 | 0.176 |
Ingresos netos antes de impuestos | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Ingresos netos después de impuestos | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Beneficio neto antes de partidas extra. Elementos | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Ingresos netos | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Beneficio neto diluido | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Promedio ponderado de acciones diluidas | 14.6206 | 8.92517 | 3.05864 | 1.86655 | 0.84249 |
BPA diluido sin partidas extraordinarias | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
Dividends per Share - Common Stock Primary Issue | |||||
BPA normalizado diluido | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
Ingresos | 0 | ||||
Total de partidas extraordinarias | |||||
Total Adjustments to Net Income | 0 | -24.437 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 14.29 | 12.386 | 11.449 | 15.378 | 9.508 |
Gastos de venta/general/administración Gastos, total | 4.699 | 4.688 | 4.832 | 5.02 | 3.815 |
Investigación y desarrollo | 9.591 | 7.698 | 6.617 | 10.358 | 5.693 |
Ingresos de explotación | -14.29 | -12.386 | -11.449 | -15.378 | -9.508 |
Otros, netos | 0.009 | -0.048 | -0.015 | -0.001 | -0.016 |
Ingresos netos antes de impuestos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Ingresos netos después de impuestos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Beneficio neto antes de partidas extra. Elementos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Ingresos netos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Beneficio neto diluido | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Promedio ponderado de acciones diluidas | 18.6982 | 13.7424 | 13.017 | 13.017 | 13.0598 |
BPA diluido sin partidas extraordinarias | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
Ingresos por intereses (gastos), netos No operativos | 1.018 | 0.437 | 0.214 | 0.056 | 0.033 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Activo Corriente | 127.075 | 46.325 | 38.958 | 38.915 | 17.463 |
Efectivo e inversiones a corto plazo | 125.508 | 44.93 | 36.244 | 37.57 | 16.369 |
Efectivo y Equivalentes | 1.853 | 22.999 | 5.432 | 5.956 | 16.369 |
Inversiones a corto plazo | 39 | 20 | 26.345 | 22.276 | 0 |
Prepaid Expenses | 1.446 | 1.274 | 2.237 | 1.345 | 1.094 |
Total Assets | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Property/Plant/Equipment, Total - Net | 0.394 | 0.966 | 2.349 | 0.056 | 0.321 |
Property/Plant/Equipment, Total - Gross | 0.377 | ||||
Accumulated Depreciation, Total | -0.321 | ||||
Other Long Term Assets, Total | 0.045 | 0.165 | 0.473 | 0.198 | 0.113 |
Total Current Liabilities | 5.203 | 6.39 | 5.032 | 4.171 | 6.016 |
Accounts Payable | 1.557 | 1.544 | 1.197 | 1.408 | 0.773 |
Accrued Expenses | 3.646 | 4.846 | 3.835 | 2.763 | 2.432 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 2.479 | |||
Total Liabilities | 5.203 | 6.787 | 6.06 | 4.227 | 6.105 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 0 | 0.397 | 1.028 | 0.056 | 0.089 |
Total Equity | 122.311 | 40.669 | 35.72 | 34.942 | 11.792 |
Common Stock | 0.013 | 0.02 | 0.012 | 0.007 | 0.024 |
Additional Paid-In Capital | 481.709 | 301.546 | 259.305 | 232.243 | 183.202 |
Retained Earnings (Accumulated Deficit) | -455.809 | -260.897 | -223.597 | -197.304 | -171.434 |
Other Equity, Total | 0 | 0 | -0.004 | 0 | |
Total Liabilities & Shareholders’ Equity | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Total Common Shares Outstanding | 13.017 | 3.34746 | 2.07227 | 0.11903 | 0.3941 |
Other Current Liabilities, Total | 0 | 0.332 | |||
Preferred Stock - Non Redeemable, Net | 96.398 | 0 | 0 | 0 | |
Cash | 84.655 | 1.931 | 4.467 | 9.338 | |
Other Current Assets, Total | 0.121 | 0.121 | 0.477 | ||
Total Preferred Shares Outstanding | 0.03146 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 114.221 | 127.075 | 134.522 | 140.052 | 147.684 |
Efectivo e inversiones a corto plazo | 112.816 | 125.508 | 131.777 | 139.52 | 146.92 |
Efectivo y Equivalentes | 46.687 | 86.508 | 131.777 | 139.52 | 146.92 |
Inversiones a corto plazo | 66.129 | 39 | 0 | 0 | 0 |
Prepaid Expenses | 1.121 | 1.446 | 2.624 | 0.411 | 0.643 |
Other Current Assets, Total | 0.284 | 0.121 | 0.121 | 0.121 | 0.121 |
Total Assets | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Property/Plant/Equipment, Total - Net | 0.228 | 0.394 | 0.557 | 0.717 | 0.874 |
Other Long Term Assets, Total | 0.204 | 0.045 | 0.05 | 0.176 | 0.182 |
Total Current Liabilities | 4.967 | 5.203 | 4.7 | 3.988 | 4.406 |
Accounts Payable | 0.931 | 1.557 | 0.574 | 0.619 | 1.809 |
Accrued Expenses | 4.036 | 3.646 | 4.126 | 3.369 | 2.597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.967 | 5.203 | 4.7 | 4.046 | 9.004 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0.058 | 4.598 | |
Total Equity | 109.686 | 122.311 | 130.429 | 136.899 | 139.736 |
Preferred Stock - Non Redeemable, Net | 96.398 | 96.398 | 96.398 | 99.77 | 240.881 |
Common Stock | 0.013 | 0.013 | 0.013 | 0.077 | 0.023 |
Additional Paid-In Capital | 484.46 | 481.709 | 480.336 | 475.499 | 329.813 |
Retained Earnings (Accumulated Deficit) | -471.132 | -455.809 | -446.318 | -438.447 | -430.981 |
Total Liabilities & Shareholders’ Equity | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Total Common Shares Outstanding | 13.017 | 13.017 | 13.0095 | 12.8248 | 3.90283 |
Total Preferred Shares Outstanding | 0.03146 | 0.03146 | 0.03146 | 0.03255 | |
Other Equity, Total | -0.053 | 0 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -194.912 | -37.3 | -26.293 | -25.87 | -27.364 |
Efectivo de actividades de explotación | -30.151 | -32.485 | -26.569 | -23.465 | -26.836 |
Efectivo de actividades de explotación | 0.026 | 0.119 | 0.304 | ||
Partidas no monetarias | 168.066 | 1.448 | 1.568 | 1.524 | 2.158 |
Intereses pagados en efectivo | 0 | 0.079 | 0.327 | ||
Cambios en el capital circulante | -3.305 | 3.367 | -1.87 | 0.762 | -1.934 |
Efectivo de actividades de inversión | -12.555 | 6.3 | -4.082 | -21.905 | 14.883 |
Gastos de capital | -0.021 | -0.033 | -0.012 | 0 | -0.057 |
Otras partidas de flujo de caja de inversión, total | -12.534 | 6.333 | -4.07 | -21.905 | 14.94 |
Efectivo procedente de actividades de financiación | 104.284 | 40.86 | 25.62 | 44.295 | 4.726 |
Emisión (retiro) de acciones, neto | 104.284 | 40.86 | 25.62 | 47.143 | 8.059 |
Emisión (amortización) de deuda, neta | 0 | -2.848 | -3.333 | ||
Variación neta de la tesorería | 61.578 | 14.675 | -5.031 | -1.075 | -7.227 |
Elementos de flujo de caja de financiación | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -15.323 | -194.912 | -185.421 | -177.55 | -170.084 |
Cash From Operating Activities | -12.559 | -30.151 | -23.865 | -16.116 | -8.716 |
Non-Cash Items | 2.672 | 168.066 | 166.702 | 165.302 | 165.037 |
Changes in Working Capital | 0.092 | -3.305 | -5.146 | -3.868 | -3.669 |
Cash From Investing Activities | -27.099 | -12.555 | 26.445 | 26.445 | 26.445 |
Capital Expenditures | 0 | -0.021 | -0.021 | -0.021 | -0.021 |
Other Investing Cash Flow Items, Total | -27.099 | -12.534 | 26.466 | 26.466 | 26.466 |
Cash From Financing Activities | 0 | 104.284 | 104.267 | 104.261 | 104.261 |
Issuance (Retirement) of Stock, Net | 0 | 104.284 | 104.267 | 104.261 | 104.261 |
Net Change in Cash | -39.658 | 61.578 | 106.847 | 114.59 | 121.99 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 11.9754 | 3351514 | 2974069 | 2022-12-31 | LOW |
Perceptive Advisors LLC | Private Equity | 7.8232 | 2189462 | 908265 | 2022-12-31 | MED |
Fairmount Funds Management LLC | Hedge Fund | 6.7939 | 1901397 | 989661 | 2022-12-31 | HIGH |
Deep Track Capital LP | Hedge Fund | 6.4907 | 1816531 | 1816531 | 2022-12-31 | MED |
Vivo Capital, LLC | Venture Capital | 6.0071 | 1681199 | 681199 | 2022-12-31 | MED |
Cormorant Asset Management, LP | Hedge Fund | 5.8957 | 1650000 | 450000 | 2022-12-31 | MED |
Altium Capital Management LP | Investment Advisor/Hedge Fund | 4.8429 | 1355372 | 910372 | 2022-12-31 | HIGH |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 4.7784 | 1337315 | 680954 | 2022-12-31 | MED |
Logos Global Management LLC | Investment Advisor | 3.0906 | 864960 | 864960 | 2022-12-31 | HIGH |
Ikarian Capital LLC | Hedge Fund | 2.4125 | 675176 | -24264 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.338 | 654326 | 123173 | 2022-12-31 | LOW |
Rosalind Advisors, Inc. | Hedge Fund | 2.3348 | 653438 | 653438 | 2021-12-31 | LOW |
Tri Locum Partners LP | Hedge Fund | 2.3273 | 651330 | 19751 | 2022-12-31 | HIGH |
Affinity Asset Advisors LLC | Hedge Fund | 1.6882 | 472482 | 72439 | 2022-12-31 | HIGH |
Sphera Funds Management Ltd. | Hedge Fund | 1.677 | 469340 | 469340 | 2022-12-31 | MED |
Ghost Tree Capital, LLC | Hedge Fund | 1.6079 | 450000 | -50000 | 2022-12-31 | HIGH |
Violin (Jonathan) | Individual Investor | 0.9409 | 263321 | 0 | 2022-04-13 | LOW |
Opaleye Management Inc. | Hedge Fund | 0.9351 | 261703 | 128203 | 2022-12-31 | MED |
Medical Strategy GmbH | Investment Advisor | 0.9026 | 252605 | -18814 | 2022-09-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 0.804 | 225000 | 225000 | 2022-12-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Astria Therapeutics, Inc. Company profile
Sobre Astria Therapeutics Inc
Astria Therapeutics, Inc, anteriormente Catabasis Pharmaceuticals, Inc, es una empresa biofarmacéutica. La compañía se centra en el desarrollo de terapias para pacientes y familias afectadas por enfermedades alérgicas e inmunológicas raras y de nicho. Su programa principal, STAR-0215, está en desarrollo preclínico para el tratamiento del angioedema hereditario (AEH). El AEH es un trastorno genético poco frecuente que se caracteriza por una hinchazón grave, recurrente, imprevisible, dolorosa y, en ocasiones, potencialmente mortal en la cara, las extremidades, el abdomen y las vías respiratorias. STAR-0215 es un anticuerpo monoclonal inhibidor de la calicreína plasmática, que está diseñado para proporcionar una prevención de ataques de larga duración para el AEH.
Industry: | Bio Therapeutic Drugs |
75 State Street
Suite 1400
BOSTON
MASSACHUSETTS 02109
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com